Seizert Capital Partners LLC Has $48.04 Million Stake in Gilead Sciences, Inc. (GILD)

Seizert Capital Partners LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 592,989 shares of the biopharmaceutical company’s stock after selling 38,280 shares during the quarter. Gilead Sciences comprises approximately 1.8% of Seizert Capital Partners LLC’s portfolio, making the stock its 18th largest holding. Seizert Capital Partners LLC’s holdings in Gilead Sciences were worth $48,044,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently made changes to their positions in GILD. Sanders Capital LLC acquired a new stake in Gilead Sciences during the 3rd quarter worth $427,585,000. Renaissance Technologies LLC grew its position in Gilead Sciences by 35.0% during the 2nd quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock worth $736,667,000 after purchasing an additional 2,700,600 shares during the last quarter. Vanguard Group Inc. grew its position in Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Gilead Sciences by 50.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 6,191,622 shares of the biopharmaceutical company’s stock worth $438,244,000 after purchasing an additional 2,062,886 shares during the last quarter. Finally, BlackRock Inc. grew its position in Gilead Sciences by 1.9% during the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares during the last quarter. Hedge funds and other institutional investors own 75.94% of the company’s stock.

In related news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total value of $5,509,508.29. Following the completion of the sale, the insider now directly owns 3,070,099 shares in the company, valued at $230,656,537.87. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. In the last three months, insiders sold 396,666 shares of company stock valued at $29,283,517. Company insiders own 1.30% of the company’s stock.

Several research analysts have issued reports on GILD shares. TheStreet raised shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. Berenberg Bank reissued a “buy” rating and set a $96.00 price objective (up from $86.00) on shares of Gilead Sciences in a research report on Wednesday, September 6th. Vetr raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 price objective on the stock in a research report on Wednesday, September 6th. Mizuho reissued a “buy” rating on shares of Gilead Sciences in a research report on Friday, September 29th. Finally, ValuEngine downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $85.03.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at $71.64 on Tuesday. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The stock has a market cap of $93,581.12, a PE ratio of 8.16, a price-to-earnings-growth ratio of -1.20 and a beta of 1.13. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. The business had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company’s revenue was down 13.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.75 earnings per share. equities analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.90%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s dividend payout ratio is presently 23.69%.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/01/02/seizert-capital-partners-llc-has-48-04-million-stake-in-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

What are top analysts saying about Gilead Sciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit